Gene Therapy in Mouse Models of Deafness and Balance Dysfunction.

Area of Science:

• Otolaryngology and Regenerative Medicine
• Developmental Neuroscience
• Genetic Therapeutics

Background:

• Inner ear diseases, affecting hearing and balance, are often treated using gene replacement, augmentation, knockdown, or knockout strategies.
• Current therapeutic modalities include viral vectors, antisense oligonucleotides (ASO), small molecules, and CRISPR-Cas9 ribonucleoprotein (RNP) complexes.

Purpose of the Study:

• To investigate the optimal timing for therapeutic interventions in mouse models of inner ear disease.
• To explore the implications of neonatal therapeutic administration for translating these therapies to human patients.
• To propose a hypothesis for preemptive fetal therapeutic strategies for genetic causes of deafness and vestibular dysfunction.

Main Methods:

• Administration of therapeutic agents (gene or drug) to early neonatal mouse inner ear models.
• Evaluation of therapeutic responses based on the timing of intervention relative to hearing onset.
• Comparison of therapeutic windows between mouse models and human fetal development.

Main Results:

• Gene or drug administration to the immature neonatal inner ear, prior to hearing onset, resulted in the most robust therapeutic responses in mouse models.
• The human auditory system develops earlier than previously thought, with hearing beginning by gestational week 19.
• This suggests a critical, early therapeutic window in human pregnancy, potentially closing in the second trimester.

Conclusions:

• Early administration of gene or drug therapies to the inner ear is crucial for maximizing therapeutic efficacy in mouse models.
• Translating these findings to humans requires considering the critical developmental window for fetal inner ear therapeutics.
• Further studies in higher vertebrate models with similar fetal hearing onset are essential for safe and effective clinical translation of inner ear gene therapies.